logo
Plus   Neg
Share
Email

Vertex's TRIKAFTA Accepted For Priority Review By Canada For Treatment Of Cystic Fibrosis

Vertex Pharmaceuticals Inc. (VRTX) said Monday that its New Drug Submission for TRIKAFTA is accepted for Priority Review by Health Canada. TRIKAFTA is the company's investigational triple combination medicine for the treatment of cystic fibrosis in people ages 12 years and older.

Following the acceptance of Priority Review, the conventional review timeline of 300 days is reduced to 180 days. The expected approval target by Health Canada is in the first half of 2021.

Cystic fibrosis is a rare, life-shortening genetic disease affecting approximately 75,000 people worldwide.

Cystic fibrosis is a progressive, multi-system disease that affects the lungs, liver, GI tract, sinuses, sweat glands, pancreas and reproductive tract. Cystic fibrosis is caused by a defective and/or missing CFTR protein resulting from certain mutations in the CFTR gene.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Shares of Netflix Inc. (NFLX) tanked 10% in extended trading session on Tuesday after the online-video streaming giant's first-quarter subscriber additions fell short of expectations. Netflix added 3.98 million subscribers globally in the quarter, far below its forecast of 6.00 million, to end the... Tech giant Apple Inc. (AAPL) on Tuesday held its first product launch event of the year and unveiled new iMac and iPad Pro, which are powered by the latest M1 chips. The Cupertino, California-based company also unveiled AirTag, a lost-device tracking gadget, and an upgraded Apple TV 4K with a new... European Medicines Agency Tuesday said it has found a possible link between the Johnson & Johnson's (JNJ) Covid-19 vaccine and rare blood clots. However, the Europe's medicines regulator pointed out that the overall benefits of getting the vaccine outweigh the risks. EMA's safety committee PRAC concluded...
Follow RTT